Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177968 | 0.89 | KDM4E (0.61) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL20931746 | 0.88 | KDM4E (0.79) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL8736385 | 0.85 | KDM4E (0.69) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL177984 | 0.84 | KDM4E (0.67) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL6325952 | 0.81 | KDM4E (0.69) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL30466074 | 0.81 | KDM4E (1.00) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL2721244 | 0.81 | KDM4E (1.00) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL4059342 | 0.81 | KDM4E (0.69) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL6203235 | 0.81 | KDM4E (0.69) | KDM4EMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL1002115 | 0.81 | KDM4E (0.68) | KDM4EMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| US-9682995-B2 | Amino-substituted isothiazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-20 | — | — | US | disclosed |
| EP-2951174-B1 | AMINO-SUBSTITUTED ISOTHIAZOLES | Bayer Pharma AG (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-20150368260-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-24 | — | — | US | disclosed |
| EP-2951174-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-09 | — | — | EP | disclosed |
| CN-104936956-A | Amino-substituted isothiazoles | Bayer Pharma AG | 2015-09-23 | — | — | CN | disclosed |
| WO-2014118186-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| WO-2005037839-A1 | NORCANTHARIDIN DERIVATIVE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | ENTOMED (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-6861420-B2 | N-substituted 1,2,4,5-tetrahydro-1H-benzo[d]azepine compounds | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1451176-A2 | BENZAZEPINE DERIVATIVES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
| US-20030149024-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-08-07 | — | — | US | disclosed |
| WO-2003045940-A2 | BENZAZEPINE DERIVATIVES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | KDM4E 2087/4885MEN1 2641/4885KMT2A 2120/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | KDM4E 2087/4885MEN1 2641/4885KMT2A 2120/4885 |
| US-20030149024-A1 | Therapeutic compounds | REN, HMGCR, RPS4X | KDM4E 2934/4885MEN1 428/4885KMT2A 4357/4885 |
| US-20150368260-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BUB1B, BUB1, CCNB1 | KDM4E 1787/4885MEN1 253/4885KMT2A 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.